Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.50 Average PT from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.80.

Several equities research analysts have issued reports on PYXS shares. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research report on Tuesday, January 23rd. SVB Leerink started coverage on Pyxis Oncology in a research note on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 target price for the company. Jefferies Financial Group reiterated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research report on Tuesday. BTIG Research initiated coverage on shares of Pyxis Oncology in a research report on Friday, February 9th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Wednesday, April 10th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC bought a new stake in Pyxis Oncology during the third quarter valued at approximately $26,000. Acadian Asset Management LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $26,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 1st quarter worth $59,000. Schulhoff & Co. Inc. purchased a new position in Pyxis Oncology in the third quarter worth $44,000. Finally, Radcliffe Capital Management L.P. bought a new position in Pyxis Oncology in the third quarter valued at $106,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $4.27 on Thursday. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The business has a 50-day moving average of $5.00 and a 200 day moving average of $3.39. The firm has a market cap of $251.42 million, a P/E ratio of -2.32 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Thursday, March 21st. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.16. As a group, research analysts predict that Pyxis Oncology will post -0.85 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.